[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fondation Ophtalmologique Adolphe de Rothschild\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":537},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,39,67,92,125,150,170,192,212,231,251,269,288,305,326,344,364,383,403,424,446,465,483,501,519],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100642098","ms-and-health-cohort-100642098",false,"NCT07645703","MS and Health Cohort","Disability Progression in Multiple Sclerosis: Determinants, Pathophysiology, and Global Health Impact","MS-Health","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Multiple sclerosis defined according to the 2024 criteria.\n* Participant affiliated with or beneficiary of a social security system, Universal - -- Health Coverage (CMU), or any equivalent healthcare coverage scheme.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Progressive disease with a life expectancy of less than one year.\n* Inability to undergo MRI\n* Person refusing to be informed of any clinically significant finding concerning their health discovered during participation in the study.\n* Patient impairment making participation in the study or understanding of the - information provided difficult or impossible.\n* Person under legal protection measures (guardianship, curatorship, or judicial protection).\n* Person deprived of liberty by judicial or administrative decision.","ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to identify clinical, biological, imaging, and environmental factors that predict the progression and severity of Multiple Sclerosis (MS). We will establish a prospective, highly phenotyped cohort of patients diagnosed with MS according to the 2024 criteria, regardless of disease form or stage.\n\nWe hypothesize that combining neurological, vascular, metabolic, neuropsychological, environmental, and imaging data (from the central nervous system and the eye) will improve the identification of markers associated with MS progression. This integrative approach will help clarify the respective roles of inflammation, vascular dysfunction, myelin repair, and neurodegeneration in disability accumulation.\n\nThe study will also evaluate the impact of MS, disability, and treatments on patients' physical, mental, and social health, as defined by the World Health Organization (WHO). These results are expected to support personalized patient management and identify modifiable risk factors to reduce disability and inform future therapeutic strategies.\n\nThe primary objective is to identify factors that worsen neurological disability in MS patients, including disease-related, comorbidity, and environmental factors. The main outcome measure is time to confirmed disability accumulation (CDA), defined as an increase in the EDSS (Expanded Disability Status Scale) score confirmed after at least 3 months.\n\nThis single-center, 5-year prospective cohort study will be conducted at Hôpital Fondation Adolphe de Rothschild (Paris, France), with annual visits. A linkage with national health data (SNDS) will be established for both MS patients and a matched control group (5:1 ratio).\n\nAdditional research procedures include:\n\nOphthalmologic exams (OCT, angio-OCT, fundus photography, pupillometry) at baseline, year 1, 3, and 5.\n\nBrain MRI with additional non-contrast research sequences (annual).\n\nClinical assessments including arterial stiffness and hearing tests.\n\nBlood sampling (up to 40 mL) for biomarker analyses and long-term biobanking (25 years).\n\nLumbar puncture if clinically indicated at baseline (with extra samples for research).\n\nPhysical activity and circadian rhythm monitoring using a wrist accelerometer for 9 consecutive days.\n\nStandardized questionnaires assessing quality of life, education, and social\u002Fprofessional impact.\n\nInclusion criteria:\n\nAge ≥ 18 years\n\nDiagnosis of MS according to 2024 criteria",[26],"Multiple Sclerosis","NOT_YET_RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-12","ACTUAL",{"date":33,"type":22},"2026-06-11",{"date":35,"type":22},"2034-06",{"name":37,"class":38},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100571704","phase-2-efficacy-of-daily-iv-administration-of-dornase-alfa-up-to-14-days-post-subarachnoid-hemorrhage-on-functional-independence-at-6-months-100571704","NCT06723717","Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months","Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months: a PROBE Multicenter Open-label Randomized Controlled Trial","RESET","Inclusion Criteria:\n\n* Hospitalization for subarachnoid hemorrhage (SAH) due to aneurysm rupture\n* Onset of SAH symptoms less than 48 hours old\n* Aneurysm exclusion performed within the last 24 hours\n* No complications during exclusion procedure, confirmed on post-procedure CT scan\n* Fisher score \\> 1 on initial brain CT scan prior to exclusion (first scan performed during emergency management)\n\nExclusion Criteria:\n\n* Unidentified date of aneurysm rupture \u002F rebleeding\n* Severe infections\n* Patient with impaired renal function (GFR \\\u003C 60ml\u002Fmin\u002F1.73m2 or serum creatinine \\>1.5 mg\u002FdL)\n* Immediate complications of neurosurgical intervention or embolization\n* Known hypersensitivity to dornase alfa, Chinese hamster ovary cell products or product excipients.\n* Previous disability (mRS\\>1 prior to SAH)\n* Pregnant or breast-feeding women (negative urine pregnancy test for women aged 49 or under)\n* Participation in another interventional drug or medical device clinical trial within the 30 days prior to inclusion.",{"count":48,"type":22},304,"INTERVENTIONAL",[51],"PHASE2","Subarachnoid hemorrhage due to aneurysm rupture (SAH) results in high mortality, while survivors frequently suffer reduced quality of life and even loss of autonomy, particularly in the active population. A significant proportion of this morbidity and mortality is linked to the occurrence of delayed cerebral ischemia (DCI), defined as a new focal neurological deficit or reduced level of consciousness unrelated to the treatment of the aneurysm or a concomitant condition.\n\nDCI mainly occurs between days 4 and 14 after SAH, with an estimated incidence of 30%, and is significantly associated with an unfavorable functional prognosis at 3 months. Currently, the only treatment for post-SAH DCI is to prevent or reverse the onset of vasospasm, with limited efficacy, for example through nimodipine administration or hemodynamic optimization. However, according to existing data, vasospasm is not the only cause of DCI, as it may occur elsewhere than in the arterial territory affected by vasospasm, or even in the absence of any vasospasm at all. Recent reviews of the literature highlight the role of microvascular thrombo-inflammation in the pathophysiology of DCI.\n\nThis phenomenon begins as soon as SAH occurs, with the appearance of multiple microvascular obstructions responsible for ischemia of downstream territories and loss of distal autoregulatory capacity. Among the effectors of thrombo-inflammation, the NETose phenomenon (production of NETs - Neutrophil Extracellular Traps or extracellular DNA network) has recently been associated with the onset of DCI. Indeed, the concentration of NETs increases in the cerebrospinal fluid (CSF) and blood of SAH patients, and correlates with the severity of the hemorrhage. Furthermore, intravenous or intraperitoneal administration of DNAse in an animal model of SAH has been shown to reduce NET concentration and improve functional prognosis by acting directly on cerebral perfusion through the reduction of micro-thrombosis.\n\nIn humans, recombinant DNAse (dornase alfa, Pulmozyme®) has marketing authorization for inhaled administration in cystic fibrosis. The toxicology report accompanying the marketing authorization demonstrates the absence of serious side effects following administration of high IV doses of Pulmozyme® in monkeys and rats. Other studies evaluating IV administration of bovine DNAse at high doses report no complications.\n\nIn 1999, a study was published evaluating intravenous (IV) Pulmozyme® in lupus patients, reporting no serious adverse events (SAEs) among the 14 patients receiving the treatment. We are currently conducting a clinical trial of the same molecule in IV administration in patients treated with mechanical thrombectomy and IV thrombolysis for ischemic stroke (NCT04785066).\n\nThis study is the first randomized clinical trial to target NETs as effectors of the thrombo-inflammation responsible for post-HSA DCI.",[54,55,56],"Ruptured Aneurysm of Intracranial Artery","SAH (Subarachnoid Hemorrhage)","Delayed Cerebral Ischemia","RECRUITING","2026-05-07",{"date":60,"type":31},"2026-05-08",{"date":62,"type":31},"2025-09-26",{"date":64,"type":22},"2028-09",{"name":37,"class":38},6,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":49,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100561071","phase-1-safety-of-a-strategy-combining-etanercept-administration-with-repeated-contrast-ultrasound-in-patients-with-alzheimers-disease-100561071","NCT06585384","Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease","Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease: Phase I Study","BRAINWAVES","Inclusion Criteria:\n\n* Positive diagnosis of Alzheimer's disease according to IWG2 criteria\n* Biological profile in favour of Alzheimer's disease\n* Age ≥ 50 years and ≤ 85 years\n* Affiliated or beneficiary of a social insurance scheme\n* Patient suffering from mild AD with little or no impact on autonomy, MMSE score ≥20 at inclusion\n* Fazekas score \\\u003C=1\n* Presence of a family or a person at home who can monitor the occurrence of adverse events\n* Sufficient command of the French language to take neuropsychological tests.\n* Have undergone a full neuropsychological assessment within 6 months.\n* If anticholinesterase treatment, stability of treatment for at least three months.\n* Signed, free and informed consent from the patient and the trusted support person.\n\nExclusion Criteria:\n\n* Patient previously treated with anti-TNF alpha (e.g. etanercept).\n* Other cause of major neurocognitive disorder.\n* Participation in another drug study\n* Absolute contraindication to MRI (e.g. pacemaker, implantable stimulator, intra-orbital metallic foreign body);\n* Contraindication to lumbar puncture.\n* History of bleeding diathesis;\n* Severe chronic respiratory disease;\n* Patient on anticoagulant therapy\n* Right-to-left shunt, severe pulmonary arterial hypertension;\n* Known cerebral vasculopathy; (Fazekas greater than 1), sequelae of ACI.\n* Treatment with Anakinra, abatacept or sulfasalazine.\n* Patients who have undergone major surgery within 28 days of the first day of the study.\n* Allergy to gadolinium, or any contraindication to contrast products used for brain imaging (in particular severe renal insufficiency with a glomerular filtration rate \\\u003C30 ml \u002F min \u002F 1.73 m2).\n* Allergy to xylocaine\n* Epilepsy or drugs that lower the epileptogenic threshold (see Appendix 6).\n* Major depressive syndrome despite appropriate treatment and\u002For psychotic symptoms (according to DSM IV);\n* MRI characteristic of an active or acute neurological process (infection, tumour) or macro-haemorrhage.\n* Non-menopausal women\n* Patient benefiting from a legal protection measure other than guardianship or curatorship.\n* Optic neuritis\n* Manifestations of multiple sclerosis\n* Live vaccinations (yellow fever, BCG) within 4 weeks of starting etanercept treatment.\n* History of hepatitis B or C\n* Patients with recent acute coronary syndrome or unstable ischaemic heart disease.\n* History of recurrent or chronic infections, or a predisposing condition such as severe or poorly controlled diabetes.\n* Patients who have undergone major surgery within 28 days of the first day of the study.\n\nContraindications related to etanercept :\n\n* Hypersensitivity to etanercept or to any of the excipients of Benepali\n* Sepsis or risk of sepsis\n* Active infection including chronic or localised infections.\n\nContraindications associated with SonoVue (ultrasound contrast medium)\n\n* Hypersensitivity to Sonovue.\n* Right-to-left shunt\n* Severe PAH (pulmonary arterial pressure greater than 90 mmHg)\n* Uncontrolled hypertension\n* Respiratory distress syndrome\n* Conditions suggesting cardiovascular instability for which dobutamine is contraindicated","50 Years","85 Years",{"count":78,"type":22},5,[80],"PHASE1","Alzheimer's disease (AD) is a clinico-pathological entity combining multiple and varied neuropathological lesions with characteristic abnormal accumulations (amyloid Beta (Aβ) plaques and neurofibrillary degeneration (NFD)), neuroinflammation, as well as neuronal and synaptic suffering.\n\nTo date, only symptomatic treatments are available, with no proven effect on neuropathological lesions or on the clinical course of the disease.\n\nAnti-TNF alpha could be a therapeutic agent of choice in the treatment of central nervous sytem (CNS) diseases with an inflammatory component, such as AD. Unfortunately, their high molecular weight prevents them from passively crossing the blood brain barrier (BBB). In a pilot study published in 2006, etanercept was administered intrathecally to AD patients with encouraging clinical effects.\n\nTransient opening of the tight junctions between the endothelial cells of the BBB by delivering High Intensity Focalised Ultrasounds (HIFU) in combination with an intravenous injection of microbubbles is a strategy that could improve bioavailability. Studies suggest that the oscillation of microbubbles in the ultrasound field generates microcurrents that induce shear forces responsible for a transient opening of the BBB. Ultrasound can be focused or unfocused and open the BBB diffusely or selectively over defined regions of the brain. This technique was first used to open the BBB in humans in 2001.\n\nTransient opening of the BBB is also thought to modulate the immune response in the CNS, leading to a reduction in the intracerebral load of Aβ. In an Alzheimer's mouse model, several studies using ultrasound devices to open the BBB have shown a reduction in the intracerebral load of Aβ (up to 75%) and an improvement in the memory faculties and cognitive performance of the animals.\n\nIn humans, two clinical trials have assessed the safety of using ultrasound-assisted BBB disruption devices in AD patients. These were the Sonocloud® (Carthera) and ExAblate® (InSightec) devices. The Sonocloud® device is an extra-dural ultrasound emitter implanted under local anaesthetic. Enrolment was completed in October 2020, but the results of the trial are not yet available (NCT03119961). The phase I study on 5 patients evaluating the ExAblate® device coupled with the injection of gas microbubbles demonstrated reversible opening of the BBB with no serious adverse effects for the patients. No effect on intracerebral Aβ load or cognitive or behavioural improvement was demonstrated. The ExAblate® device is not implantable and is therefore less invasive than the Sonocloud® device. However, it requires MRI monitoring and the transducers used often generate high levels of heat, requiring the use of a water cooling system to avoid the risk of transducer deterioration.\n\nIn this project, our aim is to assess the safety of using a non-focused ultrasound device, the General Electric VIVID S70 clinical device (CE mark G1 023782 0112 ), to perform BBB ruptures in patients suffering from AD, combined with the administration of etanercept, whose bioavailability would thus be improved.",[83],"Alzheimer Disease",{"date":85,"type":31},"2026-05-12",{"date":87,"type":31},"2025-04-15",{"date":89,"type":22},"2028-12",{"name":37,"class":38},1,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":4,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":18,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":91},"100277385","genetic-and-electrophysiologic-study-in-focal-drug-resistant-epilepsies-100277385","NCT02890641","Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies","GENEPHY","Inclusion Criteria:\n\n* Children with focal drug-resistant epilepsy including Focal Cortical Dysplasia, Hemimegalencephaly, Tuberous Sclerosis, Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), Hypothalamic Hamartomas, Sturge-Weber syndrome, Rasmussen encephalitis, gliomas\n* Their parents who have signed informed consent 1) for their child's participation (for parents) and 2) for themselves\n* Social security coverage or foreign regime recognized in France\n\nExclusion Criteria:\n\n* refusal to participate in the study\n* contraindication to anaesthesia, to MRI or to surgery\n* no medical insurance coverage","3 Months","25 Years",{"count":102,"type":22},450,"Brain somatic mutations are increasingly recognized as a major cause of focal epilepsies. These include mTOR pathway mutations underlying cortical malformations such as focal cortical dysplasia and hemimegalencephaly, and SLC35A2 mutations in MOGHE, and activating variants in the SHH pathway in hypothalamic hamartomas.\n\nThis study aims to identify brain somatic mutations using paired blood-brain samples and trace DNA from stereo-EEG electrodes, and to perform functional validation of candidate variants in children with drug-resistant focal epilepsy.",[105],"Drug-resistant Focal Epilepsies in Pediatric Population",[107,108,109,110,111,112,113,114,115,116],"Focal Cortical Dysplasia","Cortical Malformation","Hemimegalencephaly","Tuberous sclerosis","Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)","Hypothalamic hamartomas","Refractory Focal Epilepsy","Rasmussen Encephalitis","Epilepsy Surgery","Struge-Weber Syndrome","2026-04-14",{"date":119,"type":31},"2026-04-17",{"date":121,"type":31},"2015-12-17",{"date":123,"type":22},"2031-12",{"name":37,"class":38},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":49,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100413706","phase-3-reperfusion-with-p2y12-inhibitors-in-addition-to-mechanical-thrombectomy-for-perfusion-imaging-selected-acute-stroke-patients-100413706","NCT04667078","REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)","REPERFUSE","Inclusion Criteria:\n\n* Age 18 or older\n* Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and\u002For MCA) proved on CTA or MRA.\n* Symptoms onset \\\u003C 24h at imaging\n* Indication for MT and fulfillment of the following brain imaging criteria :\n\n  1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax\\>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.\n\n     OR (if perfusion imaging not available or uninterpretable) :\n  2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, \\\u003C25 mL if NIHSS 6-20 and \\\u003C50 mL if NIHSS\\>20\n\n     OR (if RAPID results are not considered reliable by the clinician) :\n  3. CORE CLINICAL MISMATCH according to the clinician evaluation\n* Pre-stroke mRS ≤ 2\n* NIHSS ≥ 6\n\nExclusion Criteria:\n\n* Contraindication to MT\n* Patient over 80 years old with \\>10 microbleeds on pre-treatment MRI\n* Pre-existing dependency with mRS ≥3.\n* Known tandem ICA-MCA occlusions requiring stenting\n* ASPECT\\\u003C6 on NCCT or DWI-MRI\n* Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol)\n* History of previous intracranial hemorrhage\n* Evidence of active bleeding or acute trauma (fracture) on examination\n* Recent surgery with a significant risk of bleeding\n* VKA oral anticoagulation with INR \\>1.7\n* Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng\u002Fml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban\n* Platelet count \\\u003C100 000\u002F mm3\n* Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test\n* Patient benefiting from a legal protection\n* Non-membership of a national insurance scheme\n* Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person\n* Participation in another study regarding AIS care interfering with this study.","80 Years",{"count":135,"type":22},368,[137],"PHASE3","The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.",[140],"Acute Ischemia","2026-02-27",{"date":143,"type":31},"2026-03-02",{"date":145,"type":31},"2022-03-02",{"date":147,"type":22},"2030-09-01",{"name":37,"class":38},13,{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":91},"100442452","description-of-lymphatic-damage-in-encephalic-venous-thrombosis-and-strictures-in-mri-a-reverse-recovery-sequence-a-pilot-study-100442452","NCT05041569","Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study","ALTREVE","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Performing an MRI injected as part of care for one of the following reasons:\n* suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC\n* venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis)\n* Express consent to participate in the study\n* Affiliate or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Absolute contraindication to MRI\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":158,"type":22},100,"Inclusion (J0):\n\n* Information\n* Verification of inclusion and non-inclusion criteria\n* Collection of consent\n* MRI examination with injection of contrast product as part of the treatment comprising the sequences:\n\nT1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research)\n\nClinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file",[161],"Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI","2026-02-17",{"date":164,"type":31},"2026-02-18",{"date":166,"type":31},"2021-12-17",{"date":168,"type":22},"2026-12",{"name":37,"class":38},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":49,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":91},"100536415","phase-2-efficacy-and-safety-of-anti-angiogenic-therapy-with-iv-bevacizumab-in-patients-with-symptomatic-cerebral-arteriovenous-malformations-100536415","NCT06264531","Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations","Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations","BevacizuMAV","Inclusion Criteria:\n\n* Patient over 18 years of age\n* With a symptomatic cerebral AVM (chronic headache, focal neurological deficit, cognitive impairment, epilepsy) of Spetzler and Martin grade III, IV or V.\n* Whose symptoms are sufficiently severe to allow significant improvement with treatment:\n\n  * MoCA score ≤ 25 and\u002For\n  * NIHSS score ≥ 4 and\u002For\n  * Epilepsy Balance Score ≥ 2 and\u002For\n  * HIT-6 score ≥ 48\n* With functional signs and symptoms not sequellar to a previous bleeding episode AND disabling (mRS\\>1)\n* Ineligible for therapeutic intervention (endovascular or neurosurgery or radiosurgery)\n* With normal bone marrow, liver and kidney function\n* For women of childbearing potential: negative pregnancy test within 14 days of inclusion and effective contraception for up to 6 months after the end of treatment\n* Having received informed consent to participate in the study\n* Affiliated or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Known allergy to bevacizumab or an excipient.\n* Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.\n* Contraindication to cerebral MRI\n* Absolute or relative contraindication to gadolinium injection\n* Proteinuria ≥ 2+ on urine dipstick (patients with proteinuria ≥2+ on urine dipstick will need to have proteinuria ≤ 1g protein on 24-hour urine to be eligible)\n* Uncontrolled hypertension (PAS \\>150 and\u002For PAD \\> 100 mmHg)\n* History of hypertensive crisis or hypertensive encephalopathy\n* Congestive heart failure (New York Heart Association Grade II or higher)\n* Previous myocardial infarction or unstable angina in the preceding 12 months\n* Symptomatic peripheral vascular disease\n* Vascular disease (aortic aneurysm, aortic dissection)\n* Major surgery, open biopsy or major traumatic lesion within 4 weeks prior to inclusion, or anticipation of the need for major surgery during the study.\n* Biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to inclusion\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess in the 6 months prior to inclusion\n* Significant unhealed wound, ulcer or bone fracture\n* Thrombotic episode within 6 months prior to inclusion\n* Atrial fibrillation\n* Patient under legal protection\n* Pregnant or breast-feeding women",{"count":179,"type":22},54,[51,137],"Brain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headaches. The management of brain AVMs is complex and requires a multidisciplinary approach in an expert center. Available therapies include endovascular embolization, neurosurgical resection and\u002For radiosurgery. These procedures carry a risk of neurological complications, and are reserved for small AVMs located at a distance from highly functional cerebral structures. To date, no drug therapy is recommended if interventional treatment is not possible.\n\nSeveral studies on resected brain AVM tissue have demonstrated that these malformations are the site of significant evolutionary inflammatory and neo-angiogenesis processes. Other studies have specifically shown that VEGF (vascular endothelial growth factor) levels are increased in AVMs. More recently, a pre-clinical study showed that anti-angiogenic treatment with Bevacizumab reduced vascular proliferation within AVMs in mice. Finally, a Phase II clinical trial in patients with Rendu-Osler disease (a genetic vascular disorder characterized by recurrent epistaxis, cutaneous telangiectasia and the presence of visceral AVMs) showed a clinical benefit of IV Bevacizumab on the symptomatology of these vascular malformations, with a reduction in the risk of hemorrhage and the extent of hepatic arteriovenous shunts. A randomized Phase III trial is currently underway (NCT03227263) to assess the efficacy of IV Bevacizumab in Rendu-Osler disease.\n\nThe aim of our study is to assess the efficacy of IV Bevacizumab on the disabling symptoms associated with symptomatic brain AVMs.",[183],"Cerebral AV Malformation","2026-01-21",{"date":186,"type":31},"2026-01-22",{"date":188,"type":31},"2026-01-16",{"date":190,"type":22},"2029-01-15",{"name":37,"class":38},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":91},"100437076","thrombo-inflammation-biomarkers-trial-in-acute-cerebral-hypoxia-100437076","NCT04971564","Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia","Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. A Case-control Trial Nested in a Cohort","RADICAL","Inclusion Criteria:\n\n\\- For cases, admitted within the first 36 hours of an acute neurological symptom related to :\n\n* An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure,\n* A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4,\n* An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission \\>4.\n\nOR\n\n* For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score.\n* Express consent to participate in the study.\n* Member or beneficiary of a social security.\n\nExclusion Criteria:\n\n* Pre-existing functional and\u002For cognitive disability\n* Patient under legal protection.\n* Pregnant or breastfeeding woman.\n* Patient with secondary haemorrhagic transformation.\n\nSecondary exclusion criteria :\n\n* Patients with an ischaemic lesion visible on imaging, unrelated to large vessel occlusion and therefore ineligible for mechanical thrombectomy.\n* Patients diagnosed with an acute non-vascular neurological pathology (migraine, epilepsy, etc.).\n* TIA patients presenting an abnormality on follow-up imaging 24-48 hours after the initial imaging.\n\nExcluded patients will be replaced.",{"count":201,"type":22},200,"The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.",[204,205],"Cerebral Hypoxia","Ischemic Stroke",{"date":186,"type":31},{"date":208,"type":31},"2024-03-19",{"date":210,"type":22},"2026-06-22",{"name":37,"class":38},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":91},"100421835","genetics-of-central-nervous-system-arteriovenous-malformations-gene-mav-100421835","NCT04772963","Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)","Genetics of Central Nervous System Arteriovenous Malformations (AVM): Genotype-Phenotype Correlation and Prognostic Impact on Patients With AVM","GENE-MAV","Inclusion Criteria:\n\n* Patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research.\n\nExclusion Criteria:\n\n* Pregnant, parturient or breastfeeding woman",{"count":221,"type":22},300,"Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.",[224],"Arteriovenous Malformations",{"date":186,"type":31},{"date":227,"type":31},"2022-02-17",{"date":229,"type":22},"2027-03",{"name":37,"class":38},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":91},"100413423","immunological-response-assessment-after-acute-ischemic-stroke-treated-with-endovascular-therapy-impress-100413423","NCT04663399","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)","IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy","IMPRESS","Inclusion Criteria:\n\n* Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,\n* Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent);\n* Affiliated or beneficiary of a social security scheme or equivalent.\n\nNon inclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Patient benefiting from a legal protection measure\n\nExclusion Criteria:\n\nNone.",{"count":240,"type":22},1200,"IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24\u002F36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.",[205,243],"Thrombectomy",{"date":245,"type":31},"2026-01-23",{"date":247,"type":31},"2023-02-23",{"date":249,"type":22},"2028-05-23",{"name":37,"class":38},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":91},"100276489","standardized-long-term-follow-up-of-patients-after-endovascular-embolization-of-a-brain-aneurysm-100276489","NCT02878967","Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm","Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain","ANENDOVASC","Inclusion Criteria:\n\n* curative embolization of a brain aneurysm\n* age \\>18 years old\n\nExclusion Criteria:\n\n* none",{"count":21,"type":22},"The time-frame and the follow-up elements after embolization of brain aneurysm are not standardized. Therefore, few reliable follow-up data are available for these patients.\n\nThis study aims at collecting standardized long term data for these patients, in order to assess the occurence of aneurysm recanalization and particularly those requiring another intervention on the aneurysm.",[262],"Aneurysm",{"date":186,"type":31},{"date":265,"type":31},"2015-11-25",{"date":267,"type":22},"2040-11-24",{"name":37,"class":38},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":91},"100276501","early-neurological-clinical-recovery-3-months-after-endovascular-treatment-of-an-acute-ischemic-stroke-100276501","NCT02879123","Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke","Assessment of Patients' Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke","AVC-endovasc","Inclusion Criteria:\n\n* acute ischemic stroke\n* endovascular treatment\n\nExclusion Criteria:\n\n* none",{"count":278,"type":22},5000,"This trial aims at collecting standardized data concerning the early neurological clinical recovery of patients, 3 months after endovascular treatment of an acute ischemic stroke.\n\nAlthough this outcome is a major issue of patients' prognosis, it is rarely collected at this stage of their follow-up.",[281],"Stroke, Acute",{"date":186,"type":31},{"date":284,"type":31},"2015-11-12",{"date":286,"type":22},"2031-05-12",{"name":37,"class":38},{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":91},"100276497","long-term-follow-up-after-embolization-of-brain-arteriovenous-malformations-100276497","NCT02879071","Long Term Follow-up After Embolization of Brain Arteriovenous Malformations","MAV-endovasc","Inclusion Criteria:\n\n* arteriovenous malformation\n* age \\> 18 years old\n\nExclusion Criteria:\n\n* none",{"count":296,"type":22},1000,"The time-frame and the follow-up elements after embolization of brain arteriovenous malformations are not standardized. Therefore, few reliable follow-up data are available for these patients. This study aims at collecting standardized long term data for these patients.",[224],{"date":186,"type":31},{"date":301,"type":31},"2015-11-26",{"date":303,"type":22},"2037-11-25",{"name":37,"class":38},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":49,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100542413","phase-3-immediate-corticosteroid-therapy-and-rituximab-to-prevent-generalization-in-ocular-myasthenia-a-probe-multicenter-open-label-randomized-controlled-trial-100542413","NCT06342544","Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","IMCOMG","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Diagnosis of ocular myasthenia within the last 6 months, defined :\n\n  * either by a typical clinical examination objectified by an expert clinician: ptosis and\u002For binocular diplopia, with a variable and fluctuating character (either spontaneous or provoked by effort or rest)\n  * or by positive anti-AChR antibodies or the presence of decrement on repetitive nerve stimulation or a positive edrophonium test\n* Ocular symptoms lasting at least one month and limited to extra-ocular muscles (weakness in one or both orbicularis oculi)\n* No non-ocular symptoms on MMS, MGC and MG-ADL.\n* Naïve to immunosuppressive therapy for ocular myasthenia gravis.\n\nExclusion Criteria:\n\n* Thymoma\n* Pupillary anomaly other than that resulting from previous local disease or surgery.\n* Signs of restrictive abduction or supraduction myopathy due to dysthyroid ophthalmopathy.\n* Graves' ophthalmopathy\n* Onset of ocular symptoms more than one year before screening date\n* Hypersensitivity to rituximab, murine proteins, prednisone, methylprednisone, aziathioprine or 6-mercaptopurine, paracetamol, dexchlorpheniramine.\n* Any infectious condition\n* Patients with severe immune deficiency\n* Severe heart failure (New York Heart Association (NYHA) Class IV) or severe uncontrolled heart disease\n* Severe hepatic insufficiency\n* Psychotic states not yet controlled by treatment\n* Hyperuricemia on xanthine oxidase inhibitors (allopurinol and febuxostat)\n* Risk of angle-closure glaucoma\n* Risk of urinary retention due to urethro-prostatic disorders\n* Vaccination with live attenuated vaccine required during study and up to 6 months after rituximab discontinuation\n* Women of childbearing age who do not wish to use effective contraception during their participation and at least 12 months after\n* Pregnant or breast-feeding women",{"count":313,"type":22},128,[137],"Myasthenia is an autoimmune disease causing dysfunction of the neuromuscular junction, resulting in fluctuating and variable muscle weakness.\n\nIn the initial phase of the disease, 70% of patients present with ocular onset myasthenia (OMG), i.e. weakness limited to the oculomotor muscles. Generalization to skeletal, bulbar and axial muscles occurs in 20-40% of cases, with a higher frequency in the first and second years, respectively 46% and 60% of generalizations. This reflects the maturation of the autoimmune response in the early years of the disease, and represents a therapeutic window of opportunity to modify the course of the disease.\n\nGeneralization is a critical event, putting the patient at risk of admission to an intensive care unit and necessitating the use of long-term immunosuppressants.\n\nThere is currently no validated strategy for preventing generalization. On the one hand, a preventive role for corticosteroid therapy in ocular-onset myasthenia has been observed in some studies, but not confirmed by others. These contradictory results may be explained by the bias of retrospective observational studies and the use of different corticosteroid administration regimens.\n\nOn the other hand, recent data on the use of low-dose Rituximab in the early phase of the disease shows greater efficacy than later use, enabling prolonged remission of the disease with a very good tolerability profile.\n\nWe propose to compare in a randomized controlled trial the usual practice with a proactive strategy with a standardized corticosteroid regimen immediate at diagnosis.\n\nPatients with ocular myasthenia are usually treated symptomatically with acetylcholinesterase inhibitors. The introduction of corticosteroids is delayed and limited to patients with persistent disabling diplopia or ptosis with occlusion. When corticosteroids are tapered off, ocular symptoms may recur. This level of corticosteroid dependence observed in patients treated for ocular myasthenia has not been specifically studied. In order to reduce the levels of corticosteroids administered and avoid recurrence of ocular symptoms and their delayed generalization, it is usually proposed to introduce another immunosuppressant.\n\nThe aim of this study is to evaluate the efficacy of a standardized proactive prevention strategy on the generalization of ocular onset myasthenias during the first 2 years. It will combine immediate treatment with corticosteroids at the time of diagnosis, with the addition of rituximab in the event of recurrence of ocular symptoms as corticosteroids are tapered off.",[317],"Ocular Myasthenia Gravis","2026-01-19",{"date":184,"type":31},{"date":321,"type":31},"2025-04-29",{"date":323,"type":22},"2029-06",{"name":37,"class":38},11,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":49,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":325},"100516060","phase-3-impact-of-annual-versus-biannual-infusions-of-ocrelizumab-in-patients-with-active-msafter-2-years-of-initial-treatment-on-freedom-from-radiological-disease-activity-at-two-years-a-multicenter-randomized-controlled-non-inferiority-trial-100516060","NCT05999604","Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial","WINDOCRE","Inclusion Criteria:\n\n1. Patient 18 years of age or older\n2. Presenting for a 4th semi-annual cycle of ocrelizumab (minimum)\n3. Requires follow-up MRI as part of treatment.\n4. Initial indication for ocrelizumab according to the marketing authorization (active MS, RR or SP form)\n5. Absence of relapse for at least 18 months (a relapse being defined as the appearance of new symptoms or worsening of existing symptoms, lasting more than 24 hours and outside a period of fever or an infectious episode; notified as a validated relapse by the neurologist in the patient's file, treated or not with boluses of Solu-Medrol).\n6. EDSS between 0 and 6 inclusive\n7. Having received informed information about the study and having signed a consent to participate in the study\n8. French language proficiency\n9. Affiliated or beneficiary of a social insurance scheme\n\nExclusion Criteria:\n\n1. Clinical forms of primary progressive MS\n2. Patients already receiving systematically spaced doses of ocrelizumab ≥ 9 months apart\n3. Contraindication to continued treatment with ocrelizumab (hypersensitivity reaction, ongoing active infection, development of malignancy since previous injection, development of severe immune deficiency)\n4. Planned pregnancy within 3 years\n5. Contraindication to MRI\n6. Contraindication to injection of contrast media\n7. Subject with severe or uncontrolled symptoms of renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric or cardiac disease, or any uncontrolled intercurrent pathology.\n8. Patient under legal protection\n9. Patients of childbearing age who do not wish to use effective contraception\n10. Pregnant or breast-feeding women",{"count":334,"type":22},244,[137],"Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and the leading cause of severe non-traumatic disability in young people, affecting 110,000 people in France. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has shown remarkable efficacy in Phase III trials on the inflammatory component of the disease, reducing the annualized relapse rate by 46% and the rate of new T2 lesions by 80% compared with interferon-β 1a.\n\nThe use of anti-CD20 agents, including ocrelizumab, is associated with an infectious risk that increases with duration of exposure, part of which is due to the development of hypo-gammaglobulinemia in relation to cumulative dose.\n\nSeveral reports suggest a persistent effect of anti-CD20 drugs in MS, with no resumption of inflammatory activity after discontinuation:\n\n* During the development of ocrelizumab, at the end of phase 2, after having received 3 or 4 semi-annual cycles of ocrelizumab, a safety period with a therapeutic window of 18 months was planned, before re-administration in the extension study. During this therapeutic window, the annualized relapse rate remained stable, and patients showed no radiological disease activity.\n* Scandinavian observational studies of \"off-label\" use of anti-CD20 in MS provide real-life evidence of the absence of recovery of clinical and radiological activity after prolonged interruption of treatment.\n\nAfter 2 years of treatment, and with disease activity under control, spacing administration intervals could reduce the risk of infection without reducing treatment efficacy. This would facilitate the decision to maintain highly active immunotherapy over the long term. In addition, this therapeutic de-escalation, by reducing the frequency of infusions and associated day hospitalizations, would help to reduce treatment management costs.\n\nOur aim is to evaluate the non-inferiority of 12-monthly spacing of ocrelizumab infusions versus the conventional 6-monthly regimen, in a population of active MS patients over 18 years of age who have already received 4 or more semi-annual cycles of treatment for 2 years.",[26],{"date":184,"type":31},{"date":340,"type":31},"2023-11-09",{"date":342,"type":22},"2029-11",{"name":37,"class":38},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":49,"phases":353,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":91},"100504391","radiohistological-correlation-of-thrombohemorrhagic-remodeling-in-the-acute-phase-of-ischemic-stroke-managed-by-decompressive-hemicraniectomy-100504391","NCT05847699","Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompressive Hemicraniectomy","SWI-SURGERY","Inclusion Criteria:\n\n* Age \\>18 years\n* Managed for sylvian ischemic stroke\n* Requiring brain MRI as part of the evaluation for possible decompressive hemicraniectomy (DH).\n\nOr\n\n* Having undergone a post-thrombectomy brain scan showing cortical hyperdensities and indication for a possible decompressive hemicraniectomy\n* Consent to participate in the study\n* Affiliated or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Absolute or relative contraindication to gadobutrol injection (history of true allergic reaction or intolerance to gadobutrol, renal insufficiency with creatinine clearance \\\u003C15ml\u002Fmin). In particular, if an allergic reaction was observed during the injection of gadobutrol performed for care during the acute phase MRI a few hours or days before.\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":352,"type":22},15,[354],"NA","Recent years have witnessed a change in the therapeutic paradigm of stroke with the advent of mechanical thrombectomy as the reference treatment.\n\nHowever, despite the achievement of effective proximal recanalization in nearly 80% of patients, nearly half of these patients have an unfavorable functional outcome. Several causes can be mentioned, such as the extent of the initial ischemic damage, the occurrence of complications related to reperfusion treatments or the occurrence of thrombosis of the downstream microvascularization. The latter is a phenomenon that has been known and studied increasingly over the last twenty years. It is the result of multiple cellular remodeling following ischemia and at the origin of an endoluminal filling by platelets, inflammatory cells and fibrin. This phenomenon introduces the fundamental difference between recanalization, i.e. the removal of the obstruction by the thrombus, and reperfusion, which translates into a satisfactory supply of oxygen to the ischemic tissues and therefore the expected result of these treatments. However, not all recanalization is necessarily accompanied by reperfusion, which is the phenomenon of no-reflow. This last situation could be explained by downstream microvascular thrombosis. Studies have shown the interest of intravenous thrombolysis associated with mechanical thrombectomy to preserve this vascular bed and improve cerebral reperfusion. More recently, a study has also shown the value of adding intra-arterial thrombolysis after mechanical thrombectomy. Nevertheless, there is currently no clinical evidence of the reality and prognostic importance of downstream microvascular thrombosis.\n\nAdvances in imaging have allowed the development of susceptibility weighted imaging (SWI) sequences with millimeter resolution, allowing a precise study of vascular damage and the appearance of previously unseen remodeling. Among them, the existence of cortical or juxta-cortical microinfarcts whose remnographic characteristics differed by the presence of a SWI hyposignal. The hypothesis evoked is that of a hemorrhagic remodeling consecutive to the barrier rupture. However, in view of the pathophysiology explained so far and the hypointense character of the thrombi on the SWI sequences, these remodeling could in fact be not microbleeding but rather markers of thrombosis in the downstream microcirculation. MRI would allow to identify the presence and the importance of microvascular thrombosis and thus to bring arguments to specifically target this microvascular component, consequence of cerebral ischemia, by antithrombotic or thrombolytic treatments.\n\nThe objective of our project is therefore to carry out a study focused on a better description and understanding of cortical and basal ganglia SWI hyposignals with a histopathological correlation and with the clinical prognosis.",[357],"Acute Ischemic Stroke",{"date":184,"type":31},{"date":360,"type":31},"2024-10-02",{"date":362,"type":22},"2029-01-01",{"name":37,"class":38},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100421083","immuno-inflammation-in-the-acute-phase-of-an-ischaemic-cerebral-accident-managed-by-decompressive-hemicraniectomy-a-case-control-study-100421083","NCT04763161","Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Case-control Study","NEUTROSURGERY","Inclusion Criteria Patients:\n\n* Collegial indication given by a neurologist, a neuroreanimator and a neurosurgeon for HD in the context of a malignant sylvian AIC.\n\nInclusion Criteria Control:\n\n\\- For neurosurgical operations in which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.\n\nNon-inclusion Criteria Patients:\n\n* HD carried out in a context of acute cerebral haemorrhage\n* Pre-existing neurological disability: modified Rankin score \\> 2\n* Patient benefiting from a legal protection measure\n\nNon-inclusion Criteria Controls:\n\n* Patient to be operated on for an acute vascular condition: meningeal haemorrhage, subdural or extradural haemorrhage, intra parenchymal haemorrhage.\n* Patient operated on for an osteomeningeal pathology present at the approach site.\n* Patient operated on for an infectious cranial or neuro-meningeal pathology.\n* Patient to be operated on as a result of an intracranial traumatic condition",{"count":372,"type":22},90,"The objective of the NEUTROSURGERY study is to describe the local and locoregional immuno-inflammatory activity in patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy compared to a control population of patients to be operated on in neurosurgery for another neurosurgical pathology.",[375],"Ischemic Cerebrovascular Accident",{"date":377,"type":31},"2026-01-20",{"date":379,"type":22},"2026-08-15",{"date":381,"type":22},"2027-03-15",{"name":37,"class":38},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":49,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100416358","immuno-inflammatory-profile-and-response-to-ischemic-stroke-reperfusion-therapies-immunostroke-100416358","NCT04701619","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies","IMMUNOSTROKE","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)\n* Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)\n* Affiliated with or beneficiary of a social security system\n\nExclusion Criteria:\n\n* Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)\n* Intracranial hemorrhage associated with AIC on initial imaging\n\nImmunosuppressive treatment or corticosteroid therapy at patient admission\n\n* Pre-existing neurological disability limiting neurological assessment at 3 months (mRS\\>2 at admission)\n* Known and diagnosed dementia pre-existing at the time of the AIC\n* Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \\\u003C15mL\u002Fmin, pregnant or breastfeeding women)\n* Patient treated by another institution and referred solely for mechanical thrombectomy\n* Patient benefiting from legal protection measures","90 Years",{"count":221,"type":22},[354],"IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.",[396,205],"Stroke",{"date":377,"type":31},{"date":399,"type":22},"2026-09-15",{"date":401,"type":22},"2028-05-15",{"name":37,"class":38},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":423},"100306395","thrombus-composition-in-ischemic-stroke-analysis-of-the-correlation-with-plasma-biomarkers-efficacy-of-treatment-etiology-and-prognosis-100306395","NCT03268668","Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis","COMPO-CLOT","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* Presenting with cerebral infarction following arterial occlusion\n* Treated for mechanical thrombectomy (whether performed or not)\n* Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure)\n* For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project).\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":240,"type":22},"The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology.\n\nThe main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.",[281,413,414,415,416],"Biological Specimen Banks","Biomarkers","Etiology","Prognosis",{"date":377,"type":31},{"date":419,"type":31},"2017-07-13",{"date":421,"type":22},"2028-01-01",{"name":37,"class":38},12,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":431,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":91},"100618678","identifying-biomarkers-in-als-patients-using-neuronal-derived-extracellular-vesicles-100618678","NCT07334743","Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles","BALNEV","Inclusion Criteria:\n\nFor patients :\n\nAge ≥ 18 years. Diagnostic suspicion of amyotrophic lateral sclerosis (ALS). Planned inpatient admission in the HFAR neurology department for the standard diagnostic work-up as part of routine care: clinical evaluation, neuropsychological assessment, nerve conduction studies\u002FEMG, motor evoked potentials (TMS\u002FMEP), brain and spinal MRI, pulmonary function testing, lumbar puncture, and standard blood tests.\n\nExplicit written informed consent to participate in the study. Affiliation with or beneficiary of a social security system.\n\nNon-inclusion criteria:\n\nPatient under legal protection\u002Fguardianship. Pregnant or breastfeeding woman. Active infection within the 4 weeks preceding biological sampling. Ongoing diagnosis and management of cancer.\n\nSecondary exclusion criterion:\n\nALS diagnosis not confirmed.\n\nFor Healthy Controls :\n\nAge ≥ 18 years. Explicit written informed consent to participate in the study. Affiliation with or beneficiary of a social security system.\n\nExclusion Criteria:\n\n* Patient under legal protection\u002Fguardianship.\n* Pregnant or breastfeeding woman.\n* Diagnosed neurological disease.\n* Self-reported cognitive impairment.\n* Active infection within the 4 weeks prior to biological sampling.\n* Current diagnosis and management of cancer.",true,{"count":433,"type":22},60,"Rationale. ENGRAILED1 (EN1) is under consideration as a therapeutic approach for amyotrophic lateral sclerosis (ALS). To assess EN1 target engagement in patients, we aim to identify EN1-responsive biomarkers suitable as Prentice-style surrogate endpoints. We will discover candidates by RNA-seq of neuron-derived extracellular vesicles (NVEC) immuno-isolated from blood. Establishing such biomarkers would enable and de-risk early-phase (I\u002FII) EN1 trials.\n\nPrimary endpoint. Discovery: RNA-seq identification of circulating NVEC-borne biomarkers that differ between sporadic ALS patients and healthy controls.\n\nEN1 modulation: Demonstration that these biomarkers are modulated by EN1 in En1+\u002F- mouse models and in ALS patient iPSC-derived motor neurons.\n\nDesign. Prospective cohort, N=60 (30 sporadic ALS; 30 healthy controls matched on age\u002Fsex).\n\nPopulation. Adults undergoing diagnostic work-up for suspected sporadic ALS; healthy volunteers without neurological disease.\n\nKey procedures and timeline. Baseline (M0, inpatient): ALSFRS-R, MRC, hand dynamometry, eye-movement recording (MOC); NCS\u002FEMG (NUMIX), TMS\u002FMEP with cortical excitability; neuropsychology; brain \\& spinal MRI; pulmonary function testing; CSF (10 mL) and blood (15 mL) for clinical labs and research (NVEC immunocapture → RNA-seq; proteomics).\n\nFollow-up: M6 clinic visit (repeat clinical\u002Felectrophysiology\u002Fneuropsychology\u002FPFTs as per care) with blood (15 mL); additional routine follow-ups at M12, M18, M24 (clinical; MOC at M12 and M24).\n\nControls: single visit with blood (3×5 mL EDTA) and cortical excitability; brain MRI for targeting.\n\nSample size. 60 participants total (30 ALS, 30 controls).",[436,437],"Amyotrophic Lateral Sclerosis","ENGRAILED1","2025-12-31",{"date":440,"type":31},"2026-01-12",{"date":442,"type":31},"2025-09-17",{"date":444,"type":22},"2029-09",{"name":37,"class":38},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":91},"100561425","detection-of-spinal-cord-lesions-using-the-mp2rage-sequence-in-inflammatory-diseases-of-the-neuraxis-100561425","NCT06589999","Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis","SCOUT-MS","Inclusion Criteria:\n\n* Patient aged over 18 years\n* scheduled to undergo 1.5T or 3T MRI of the spinal cord as part of an initial assessment or reassessment of inflammatory neuraxial disease.\n* Express consent to participate in the study\n* Member or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant women\n* Absolute or relative contraindication to 1.5T or 3T MRI",{"count":454,"type":22},196,"Since the last revision of the MRI guidelines in multiple sclerosis (MS, MAGNIMS) and the McDonald criteria in 2017, all spinal cord lesions must be counted to increase the sensitivity and specificity of the diagnosis of MS. Focal lesions of the spinal cord are more frequently located in the cervical segments than in the lower segments of the spinal cord and occupy the lateral and posterior columns, although the central grey matter may not be spared. Cervical involvement is difficult to study because of the small size of the lesions and the loss of signal in the cervical region. As a result, the detection of cervical lesions on MRI is sub-optimal.\n\nIn this context, standardised acquisition protocols have been proposed.\n\nFor MRI of the spinal cord, at least two of the following sagittal sequences are recommended: T2, STIR, double inversion recovery, T1 with gadolinium injection, and\u002For T2 axial acquisitions.\n\nRecently, our team validated the superiority of 3D PSIR and 3D FGAPSIR sequences, which offer better detection performance than T2 and STIR on 3 Tesla MRI.\n\nOther studies have also shown the contribution of the MP2RAGE sequence to the detection of spinal cord lesions in MS, compared with the set of sequences classically recommended. The MP2RAGE sequence is a T1 sequence, which creates a composite image, limiting field inhomogeneity bias while providing a quantitative T1 map. It has recently been optimised for the spinal cord, and has been only minimally evaluated in the context of MS.\n\nThe aim of this study is to evaluate the effectiveness of the MP2RAGE sequence in comparison with the set of conventional sequences recommended for the detection of spinal cord lesions in MS patients.",[26],"2025-12-30",{"date":459,"type":31},"2026-01-05",{"date":461,"type":31},"2024-07-31",{"date":463,"type":22},"2026-07",{"name":37,"class":38},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":91},"100504945","impact-of-the-spatial-resolution-of-several-contrast-enhanced-3d-t1-wi-sequences-when-diagnosing-giant-cell-arteritis-gca-100504945","NCT05854927","Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)","SPARTA","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Referred for imaging for an injected MRI for suspected GCA\n* Suspicion of GCA based on the presence of three major criteria or two major and one minor criteria defined as follows:\n\n  * Major criteria: Age \\> 50 years; Headache of recent onset; Claudication of the jaw, tongue or swallowing disorders; Visual problems (blindness, diplopia, blurred vision - including visual accidents occurring during the first week of treatment); Sedimentation rate at 1st hour \\> 50 and\u002For CRP \\> 8mg\u002Fl\n  * Minor criteria: Hypersensitivity or induration of the scalp or presence of nodules remote from the temporal artery; Temporal artery abnormalities on palpation; Facial pain or feeling of facial edema; General signs (fever \\>38°C, weight loss \\>10%, anorexia, malaise, asthenia).\n* Cconsent to participate in the study\n* Affiliated or beneficiary of a social security plan\n\nExclusion Criteria:\n\n* Newly diagnosed malignant disease (diagnosed less than one year prior to inclusion)\n* Active infectious disease\n* Autoimmune disease (especially but not limited to: Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, periarteritis nodosa).\n* Systemic corticosteroid therapy for more than 10 days at high dose (\\>0.5mg\u002Fkg\u002Fd of prednisone)\n* Contraindication to MRI\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":473,"type":22},133,"Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries. Its incidence is estimated at 17.8\u002F100,000 in subjects over 50 years old (and 46\u002F100,000 in subjects over 70 years old). This disease remains a severe pathology due in particular to its vascular, ophthalmological, neurological, cardiac and aortic complications. In case of suspected CAG, management is a real therapeutic emergency. Indeed, only corticosteroid therapy started as early as possible can prevent the occurrence of these complications.\n\nThe gold standard for the diagnosis of CAG has long been the temporal artery biopsy, but imaging is now considered as a 1st line diagnostic examination for the diagnosis of CAG according to the EULAR 2018 recommendations. Notably, temporal artery MRI has excellent sensitivity and specificity for diagnosis.\n\nHowever, the high diagnostic performance of MRI has been achieved by performing 3D T1 black blood and fat saturation sequences in high resolution (\\\u003C0.7mm), which are not accessible in all centers in France and worldwide.\n\nThe realization of identical sequences with a lower resolution could allow a greater generalization of these sequences and improve the diagnostic management of GCA patients, including in non-expert centers.\n\nThe objective of our study is to investigate the diagnostic performance of several 3D T1 black blood and fat saturation sequences for the diagnosis of GCA.",[476],"Giant Cell Arteritis",{"date":459,"type":31},{"date":479,"type":31},"2024-01-10",{"date":481,"type":22},"2027-06",{"name":37,"class":38},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":431,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":91},"100493184","motivational-behavioral-and-functional-mri-impairment-in-patients-with-chronic-neuropathic-pain-100493184","NCT05701852","Motivational Behavioral and Functional MRI Impairment in Patients With Chronic Neuropathic Pain","MOTION","Inclusion Criteria:\n\n* For cases: patients managed in the neurosurgery department or at CETD for chronic neuropathic pain, of central or peripheral origin.\n* For controls: matched to a case on age (±5 years) and sex\n\nExclusion Criteria:\n\n* Neurodegenerative or inflammatory neurological pathology\n* Clinical depressive syndrome\n* High doses of opioid treatment (greater than 100 mg\u002Fday of morphine equivalent)\n* Impaired judgment or inability to receive information that does not allow the performance of behavioral tasks\n* Absolute contraindication to MRI (e.g. pacemaker, implantable pacemaker, metallic intra-orbital foreign body)",{"count":491,"type":22},50,"The main hypothesis of this study is that the alteration of the reward circuitry underlying the motivational deficit in chronic pain patients compared to healthy subjects results in a decrease in the capacity for reward learning. The fMRI studies have shown that this type of learning depends on the dopaminergic system innervating key regions of the reward system.",[494],"Chronic Pain",{"date":459,"type":31},{"date":497,"type":31},"2023-12-19",{"date":499,"type":22},"2027-05",{"name":37,"class":38},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":91},"100492172","brain-representation-of-acquisition-in-humans-of-motor-sensory-skills-100492172","NCT05688683","Brain Representation of Acquisition in Humans of Motor-Sensory Skills","BRAHMS","Inclusion Criteria:\n\n* Benefiting from an intracranial brain recording during a programmed surgery in awake condition.\n\nExclusion Criteria:\n\n* Patient with complete deafness\n* Patient with a disorder or impairment that does not allow him\u002Fher to perform the experimental task according to the investigator's judgment",{"count":491,"type":22},"Interactions between the perceptual and motor systems are fundamental to the performance of complex motor tasks and are at the heart of the fine motor control required for the production of complex sounds such as speech production or playing a musical instrument. In such situations, the brain must learn to generate relevant motor commands to a sound-producing system with fixed physical characteristics, such as the vocal tract or a musical instrument.\n\nNo study has yet been able to directly test the dynamic aspect of this sensorimotor learning in an acoustic production task with fine motor control.\n\nThe Adolphe de Rothschild Foundation Hospital takes care of patients requiring awake surgery. During these procedures, a direct cortical recording, called electro-corticography, is performed in order to better delineate the tumor or epileptogenic resection area. Reference recordings are made in healthy areas at a distance from the lesion site making it possible to record normal brain activity.\n\nIn this case, we would propose to the patient to use a tool similar to the theremin (a musical instrument the size of a golf ball whose displacement in space modulates the frequency and the harmonics of a sound). The patient should therefore learn in order to create relevant motor patterns.",[511,512],"Epilepsy","Cerebral Tumor",{"date":459,"type":31},{"date":515,"type":31},"2023-01-04",{"date":517,"type":22},"2028-03",{"name":37,"class":38},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":91},"100462364","mri-versus-ocular-ultrasonography-for-a-non-contact-evaluation-of-ocular-layers-100462364","NCT05300698","MRI Versus Ocular UltraSonography for a Non Contact Evaluation of Ocular Layers","MOUSE","Inclusion Criteria:\n\n* Patient over 18 years old\n* Addressed in imaging for the realization of an ultrasound diagnostic eye\n* Express consent to participate in the study\n* Member of or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient with an absolute or relative contraindication to MRI (pacemaker or neurosensory stimulator or defibrillator implantable; ocular or cerebral ferromagnetic foreign body; claustrophobia)\n* Absolute or relative contraindication to the injection of gadolinium (history of an allergic reaction to a product of contrast, bronchial asthma, allergic terrain, renal failure with serum creatinine clearance \\\u003C30 mL\u002Fmin)\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman: a pregnancy test in the woman of childbearing age is to be carried out before inclusion",{"count":527,"type":22},30,"D0: inclusion visit\n\n* information\n* Realization of the ocular ultrasound (care)\n* Collection of consent\n* Realization of high resolution MRI with injection of contrast product (duration of 30 minutes) For the realization of the MRI, the contrast product used is the gadobutrol. The dose, the lowest allowing an enhancement of sufficient contrast for diagnostic purposes (0.1 mmol\u002Fkg body mass body), is administered as a bolus intravenously in the lying patient. The MRI examination can begin immediately after injection. The patient should be monitored for at least half an hour after this, the majority of undesirable effects occurring at the during this period. The indication of ocular ultrasound and ophthalmological follow-up of the patient up to 1 month after inclusion will be collected at from their medical records.",[530],"Describe Ultrasound Matches and Disagreements Ocular and MRI",{"date":459,"type":31},{"date":533,"type":31},"2024-01-23",{"date":535,"type":22},"2026-11",{"name":37,"class":38},""]